Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

The Lancet Neurology

Volumn 8, Issue 9, 2009, Pages 791-801

  Tabrizi, Sarah J ^a   Langbehn, Douglas R ^b   Leavitt, Blair R ^c   Roos, Raymund AC ^d   Durr, Alexandra ^e   Craufurd, David ^f   Kennard, Christopher ^g   Hicks, Stephen L ^g   Fox, Nick C ^a   Scahill, Rachael I ^a   Borowsky, Beth ^h   Tobin, Allan J ^h   Rosas, H Diana ⁱ   Johnson, Hans ^j   Reilmann, Ralf ^k   Landwehrmeyer, Bernhard ^l   Stout, Julie C ^m,n  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f ST MARY S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h CHDI MANAGEMENT CHDI FOUNDATION   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF IOWA   (United States)

^k UNIVERSITY OF MÜNSTER   (Germany)

^l UNIVERSITY OF ULM   (Germany)

^m MONASH UNIVERSITY   (Australia)

ⁿ INDIANA UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; EYE MOVEMENT CONTROL; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; AGED; ATROPHY; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; YOUNG ADULT;

EID: 68249113963     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70170-X     Document Type: Article

References (40)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
2. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 11 (1996) 136-142
3. Marder K., Zhao H., Myers R.H., et al. Rate of functional decline in Huntington's disease. Neurology 54 (2000) 452-458
4. Duyao M., Ambrose C., Myers R., et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4 (1993) 387-392
5. Paulsen J.S., Hayden M., Stout J.C., et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 63 (2006) 883-890
6. Kirkwood S.C., Siemers E., Hodes M.E., Conneally P.M., Christian J.C., and Foroud T. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J Neurol Neurosurg Psychiatry 69 (2000) 773-779
7. Gordon A.M., Quinn L., Reilmann R., and Marder K. Coordination of prehensile forces during precision grip in Huntington's disease. Exp Neurol 163 (2000) 136-148
8. Berrios G.E., Wagle A.C., Markova I.S., Wagle S.A., Rosser A., and Hodges J.R. Psychiatric symptoms in neurologically asymptomatic Huntington's disease gene carriers: a comparison with gene negative at risk subjects. Acta Psychiatr Scand 105 (2002) 224-230
9. Aylward E.H., Sparks B.F., Field K.M., et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63 (2004) 66-72
10. Thieben M.J., Duggins A.J., Good C.D., et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 125 (2002) 1815-1828
11. Ciarmiello A., Cannella M., Lastoria S., et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 47 (2006) 215-222
12. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., and Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65 (2005) 745-747
13. Zimbelman J.L., Paulsen J.S., Mikos A., Reynolds N.C., Hoffmann R.G., and Rao S.M. fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc 13 (2007) 758-769
14. Weeks R.A., Piccini P., Harding A.E., and Brooks D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 40 (1996) 49-54
15. Yamamoto A., Lucas J.J., and Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101 (2000) 57-66
16. Langbehn D.R., Brinkman R.R., Falush D., Paulsen J.S., and Hayden M.R. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics 65 (2004) 267-277
17. Kloppel S., Draganski B., Golding C.V., Chu C., Nagy Z., Cook P.A., et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 131 (2008) 196-204
18. Golding C.V., Danchaivijitr C., Hodgson T.L., Tabrizi S.J., and Kennard C. Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology 67 (2006) 485-487
19. Penney Jr. J.B., Vonsattel J.P., MacDonald M.E., Gusella J.F., and Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41 (1997) 689-692
20. Sanchez-Pernaute R., Garcia-Segura J.M., Barrio Alba A., Viano J., and de Yebenes J.G. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 53 (1999) 806
21. Paulsen J.S., Langbehn D.R., Stout J.C., et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79 (2008) 874-880
22. Shoulson I., and Fahn S. Huntington disease: clinical care and evaluation. Neurology 29 (1979) 1-3
23. Huntington Study Group. Unified Huntington's Disease Rating Scale-99 (1999), Huntington Study Group
24. Freeborough P.A., Fox N.C., and Kitney R.I. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 53 (1997) 15-25
25. Magnotta V.A., Harris G., Andreasen N.C., O'Leary D.S., Yuh W.T., and Heckel D. Structural MR image processing using the BRAINS2 toolbox. Comput Med Imaging Graph 26 (2002) 251-264
26. Fischl B., Liu A., and Dale A.M. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging 20 (2001) 70-80
27. Hicks S.L., Robert M.P., Golding C.V., Tabrizi S.J., and Kennard C. Oculomotor deficits indicate the progression of Huntington's disease. Prog Brain Res 171 (2008) 555-558
28. Reilmann R., Kirsten F., Bohlen S., Saemann P., Merl T., and Auer D. Multimodal objective assessment of motor deficits in Huntington's disease using isometric force analysis. J Neurol Neurosurg Psychiatry 76 (2005) A33
29. Rao A.K., Muratori L., Louis E.D., Moskowitz C.B., and Marder K.S. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord 23 (2008) 1100-1107
30. Craufurd D., Thompson J.C., and Snowden J.S. Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol 14 (2001) 219-226
31. Paulsen J.S., Magnotta V.A., Mikos A.E., et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 59 (2006) 57-63
32. Henley S.M., Wild E.J., Hobbs N.Z., et al. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord 24 (2009) 932-936
33. Rosas H.D., Liu A.K., Hersch S., et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 58 (2002) 695-701
34. Wolf R.C., Vasic N., Schonfeldt-Lecuona C., Landwehrmeyer G.B., and Ecker D. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain 130 (2007) 2845-2857
35. Smith M.A., Brandt J., and Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 403 (2000) 544-549
36. Munoz D.P., and Everling S. Look away: the anti-saccade task and the voluntary control of eye movement. Nat Rev Neurosci 5 (2004) 218-228
37. Henley S.M., Wild E.J., Hobbs N.Z., et al. Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia 46 (2008) 2152-2160
38. Johnson S.A., Stout J.C., Solomon A.C., et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 130 (2007) 1732-1744
39. Julien C.L., Thompson J.C., Wild S., et al. Psychiatric disorders in preclinical Huntington's disease. J Neurol Neurosurg Psychiatry 78 (2007) 939-943
40. Tibben A. Genetic counselling and presymptomatic testing. In: Bates G.P., Harper P.S., and Jones L. (Eds). Huntington's disease (2002), Oxford Medical Publishers, Oxford 198-250